Amanote Research
Register
Sign In
Psy187 - The Quantity and Quality of Evidence Supporting European Marketing Authorisation of Orphan Drugs: Comparison of Rare Oncology Versus Rare Disease
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.2761
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
S. Kelly
Publisher
Elsevier BV
Related search
Psy180 - Uk Health Technology Assessment of Orphan Drugs for Rare Oncology Versus Rare Disease: Does Orphan Designation Make Any Difference in Hta Process?
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
First International South Caucasian Conference on Rare Diseases and Orphan Drugs
European Journal of Pediatrics
Child Health
Pediatrics
Perinatology
Payer Management and Pricing Dynamics for Non-Oncology Pharmacy Benefit Orphan Drugs for Rare Diseases in the United States Launched 2004-2014
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Psy60 - Orphan Versus Ultra-Orphan Drugs Prices in England
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Graft-Versus-Host Disease: A Rare Complication of Device Implantation
HeartRhythm Case Reports
Cardiovascular Medicine
Cardiology
A Proposed Definition of Rare Diseases for China: From the Perspective of Return on Investment in New Orphan Drugs
Orphanet Journal of Rare Diseases
Medicine
Genetics
Pharmacology
PHP46 Market Uptake of Orphan Drugs – A European Analysis
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn22 - Marketing Authorisation Practice of the European Medicines Agency (Ema) in Oncological Indications
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Rare Diseases, Drug Development, and AIDS: The Impact of the Orphan Drug Act
Milbank Quarterly
Health Policy
Public Health
Occupational Health
Environmental
